The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000631303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
23/03/2026
Date registered
Help: Date registered
22/05/2026
Date last updated
Help: Date last updated
22/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
22/05/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Safety and efficacy of autologous fat grafting to reduce the risk of oesophageal stricture formation after endoscopic resection
Scientific title
The safety and efficacy of Autologous fat grafting for stricture reduction in high stricture-risk oesophageal endoscopic submucosal dissection (ESD) and Endoscopic Mucosal Resection (EMR).
Additional trial identifiers [1] 316845 0
nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Oesophageal dysplasia 341215 0
oesophageal cancer 341216 0
Condition category
Condition code
Oral and Gastrointestinal 337305 337305 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Cancer 337484 337484 0 0
Oesophageal (gullet)

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
1. patients in total with either squamous cell or Barrett’s oesophagus associated dysplasia or intramucosal cancer (T1a) who require 75% or greater circumferential endoscopic resection will be enrolled.
2. Endoscopic resection will then be performed as per standard Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD) technique. The total duration of resection varies from approximately 1 -2 hours and will differ with every patient.
3. Fat harvesting procedure and preparation performed
- Fat harvesting from appropriate site by plastic surgeon
4. Injection of autologous fat after endoscopic resection - this involves decanting harvested fat into a syringe then injecting it endoscopically into the ESD or EMR defect.
- duration of procedure for hat harvesting and injection typically adds 30 mins to the resection time.
- occurs once only
5. Intraprocedural antibiotics cephazolin 1gram and metronidazole 500mg both intravenously
There is no routine monitoring of adherence or fidelity as this is not required, the intervention occurs intraprocedurally and thereafter all clinical outcomes are assessed at outpatient visits/ at routine endoscopy as below. Patients receive reminders for their upcoming appointments.
Intervention code [1] 333547 0
Prevention
Intervention code [2] 333701 0
Treatment: Surgery
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344823 0
o Safety:
Timepoint [1] 344823 0
Measured both on day of the procedure and complications for up to 30 days post procedure- 2 weeks, 4 weeks, 6 weeks, 3 months.
Primary outcome [2] 344824 0
o Technical efficacy:
Timepoint [2] 344824 0
Measured as successful harvesting and injection on the day of procedure
Secondary outcome [1] 459420 0
• Clinical efficacy of autologous fat graft injection
Timepoint [1] 459420 0
2 weeks post intervention, 4 weeks post intervention and 3 months post intervention

Eligibility
Key inclusion criteria
1. Aged 18 years old and over
2. Medically fit for anaesthesia
3. Squamous cell or Barrett’s oesophagus with dysplasia or intramucosal cancer
4. 75% or greater oesophageal circumferential resection either via EMR or ESD
5. Informed consent obtained from the patient or legal representative
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Aged under 18 years old
2. Pregnant at enrolment
3. Unable to obtain informed consent from the patient or legal representative
4. Medically unfit for anaesthesia
5. Current smokers
6. Previous radiotherapy to the involved oesophagus
7. Irreversible coagulopathy: INR >1.5
8. Irreversible thrombocytopenia: platelet count <50 x 109/L, thrombocytopenia confirmed by manual count
9. Dual antiplatelet therapy or therapeutic anticoagulation that cannot be withheld for the procedure
10. Presence of oesophageal varices
11. Immunocompromised

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29288 0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Recruitment postcode(s) [1] 45607 0
3065 - Fitzroy

Funding & Sponsors
Funding source category [1] 321448 0
Hospital
Name [1] 321448 0
St Vincent's Hospital Melbourne
Country [1] 321448 0
Australia
Primary sponsor type
Hospital
Name
St Vincent's Public Hospital Melbourne
Address
Country
Australia
Secondary sponsor category [1] 324193 0
None
Name [1] 324193 0
Address [1] 324193 0
Country [1] 324193 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319979 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 319979 0
Ethics committee country [1] 319979 0
Australia
Date submitted for ethics approval [1] 319979 0
Approval date [1] 319979 0
13/02/2026
Ethics approval number [1] 319979 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149026 0
A/Prof Bronte Holt
Address 149026 0
St Vincent's Hospital Melbourne, 41 victoria parade Fitzroy 3065
Country 149026 0
Australia
Phone 149026 0
+61390016924
Fax 149026 0
Email 149026 0
Contact person for public queries
Name 149027 0
Kathryn Gazelakis
Address 149027 0
St Vincent's Hospital Melbourne, 41 Victoria parade Fitzroy 3065
Country 149027 0
Australia
Phone 149027 0
+61403640609
Fax 149027 0
Email 149027 0
Contact person for scientific queries
Name 149028 0
Kathryn Gazelakis
Address 149028 0
St Vincent's Public Hospital Melbourne, 41 Victoria Parade, Fitzroy Melbourne 3065
Country 149028 0
Australia
Phone 149028 0
+61403640609
Fax 149028 0
Email 149028 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.